Chord Therapeutics
Geneva
About Chord Therapeutics
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG). The company was founded in 2014 and based in Geneva, Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.0M
- Funding stage: M&A
- Last round: Series A (Oct 2020)
- Website: chordtherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/chord-therapeutics-131831 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.